Navigation Links
FDA Advises Against Avastin as Treatment for Breast Cancer
Date:12/16/2010

By Amanda Gardner
HealthDay Reporter

THURSDAY, Dec. 16 (HealthDay News) -- Federal health officials on Thursday recommended revoking approval of the drug Avastin to fight breast cancer, citing the medication's poor performance in follow-up studies and its potential for serious side effects.

But the recommendation, announced by U.S. Food and Drug Administration (FDA) officials at a news conference, will not immediately affect breast cancer patients' access to the drug or limit use of the Avastin (bevacizumab) for advanced colon, lung, kidney and brain cancer.

Nevertheless, the decision could leave breast cancer patients who have responded well to the drug wondering what to do next.

"FDA has taken the first step to removing the breast cancer indication from the label of the cancer drug Avastin," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER), announced at the news conference. "This is a first step in a process and will not have an immediate impact on use of Avastin or the drug's availability."

"Oncologists currently treating patients with Avastin should use medical judgment in deciding whether to continue treatment or explore other treatment options," she added.

The drug's maker, Genentech, has been notified of the recommendation in writing and now has 15 days to request a proceeding to dispute the FDA recommendation and present additional evidence. The company "has not agreed to remove the breast cancer indication voluntarily," the FDA noted in a statement released Thursday.

Some doctors expressed concern at the decision.

"This is a tough issue. There are women who have clearly responded to the treatment, [and] this is going to be a very difficult pill to swallow for those women," said Dr. Neil Spector, professor of medicine at Duke Cancer Institute in Durham, N.C.

"There's a very real possibility that there may be a subgroup of women that
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises
2. Keep Stress Off the Holiday Meal Menu, Expert Advises
3. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
4. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
5. AMA Joins First Lady in Fight Against Childhood Obesity
6. The Alliance for a Healthier Generation Names Celtics Captain Paul Pierce National Athlete Spokesperson in the Fight Against Childhood Obesity
7. Tiny fruit fly could offer big clues in fight against obesity, researcher says
8. Compound shows promise against intractable heart failure
9. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
10. NSAIDs Wont Shield Against Skin Cancer
11. A Healthy Diet Remains Your Best Weapon Against the #1 Killer: Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advises Against Avastin as Treatment for Breast  Cancer
(Date:7/11/2014)... 11, 2014 As transvaginal mesh ... Johnson & Johnson’s Ethicon Inc. unit continue to ... that the Texas Attorney General’s Office has acknowledged ... surgical mesh products used to treat pelvic organ ... report from kens5.com, the probe began nearly two ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... was thought to be cured by immediate and aggressive drug ... the AIDS-causing virus in her bloodstream, disappointed federal officials announced ... had remained virus-free even though she stopped taking HIV medications ... remission would open the door to a functional cure for ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & ... - 2018,” defines and segments the specialty synthetic ... and forecast of the volumes and values of ... meta aramids, UHMW Polyethylene, carbon fiber, partially oxidized ... fiber, PBO fiber, and liquid crystal polymer fiber ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket Down ... at the Concord Pavilion . When it comes to the ... Luke Bryan. The 37-year-old Georgia native is one of the biggest ... the entertainment business. Bryan is currently out on his “That’s My ... the many stops the tour will be making through the rest ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... Oct. 8 Thousands of people around the world ... poetry and speak out to raise awareness and funds ... on Saturday, October 10, 2009. , "Discovering your Voice," ... 2009, stresses the need to hear the voices of ...
... Quantros, a leading provider of safety and quality ... industry, today announced significant updates to its Regulatory ... coincide with National Hospital Quality Measures (NHQM) updates ... will now include expanded tracking of venous thromboembolism ...
... Sysmex America, Inc. today announced that Tom Lindsay ... Sales. Lindsay will be responsible for sales strategy ... and retention of the company,s sales professionals. ... will focus on cross-functional collaboration that enables Sysmex to ...
... 8 American Laser Centers, the leading provider of aesthetic ... CEO, to oversee the continued growth and national expansion of ... ALC,s board of managers, and is responsible for the strategic ... the role of CEO from James McDermott. , American Laser ...
... The University of Guam received an $8,000,000 five-year ... to support a strong national cancer program aimed ... and the impact on minority populations. The grant ... research capabilities at the University of Guam, Increase ...
... Elsevier, a world-leading publisher of medical information products and ... Medical Press (PUMP) it has donated over 5,000 books ... The initiative is supported by the Development Centre for ... book donation is in line with the spirit of ...
Cached Medicine News:Health News:Discovering the Voice of Hospice and Palliative Care Worldwide: World Hospice and Palliative Care Day - October 10, 2009 2Health News:Quantros Expands RRM Solution With New Quality Measures 2Health News:Sysmex America Names National Sales Director 2Health News:American Laser Centers Names Health Care Veteran Steven Straus CEO 2Health News:University of Guam Cancer Research Center receives $8M grant 2Health News:Elsevier's Health Sciences Division and Peking University Medical Press cooperate on book donation 2
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today ... 30, 2013, compared to sales of $2,202,000 for the prior ... this quarter has also shown growth over the preceding quarter,s ... of this fiscal year. Markets that experienced sales increases over ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Mass., Jan. 4, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, today announced that the United States ... designation for HT-100 for treatment of Duchenne muscular ... neuromuscular disorder, which afflicts approximately 1 in 3,500 ...
... Pa., Jan. 4, 2012  Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) ... 30th Annual J.P. Morgan Healthcare Conference to be held ... in San Francisco, CA.  Mr. Adrian Adams, Chief Executive ... of the Company and its product pipeline at 2:00 ...
Cached Medicine Technology:Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy 2Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy 3Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 3Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 4
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
Medicine Products: